MedTrace Logo

A Pilot Clinical Trial With Tocotrienol on Breast Cancer

NCT01157026 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2010-07-05

No results posted yet for this study

Summary

Tocotrienol Rich Fraction (TRF) in combination with Tamoxifen will improve breast cancer specific survival and recurrence free survival, in women with early breast cancer and estrogen receptor positive tumors.

Conditions

Interventions

DIETARY_SUPPLEMENT

Tocotrienol Rich Fraction (TRF)

Tocotrienol Rich Fraction (200mg), daily for five years

OTHER

placebo plus tamoxifen

20mg tamoxifen daily

Sponsors & Collaborators

  • Malaysia Palm Oil Board

    lead OTHER_GOV

Principal Investigators

  • Kalanithi Nesaretnam, PhD · Malaysia Palm Oil Board

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2006-11-30
Completion
2010-01-31

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01157026 on ClinicalTrials.gov